Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioma 8Multiple Myeloma 7Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Wilms Tumor 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Pancreatic Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Malignant Solid Neoplasm 2

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1erdafitinib 1X-Rays 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Diffusion Tensor Imaging 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Familial ependymoma × X-Rays × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡